DOCSLIB.ORG

Supplementary Table 1 (JB00889-05 Revised)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Table 1 (JB00889-05 Revised) Supplementary Table 1 Transcriptome profiles of Rhodopseudomonas palustris strains Cells grown in N-fixing mudium (N-fixing conditions) were compared with cells grown in the same medium supplemented with ammonium sulfate (non-N-fixing conditio Remark 1 Profile was determined by 3 comparative experiments and 2 calibration experiments, and two slides were used in each experiment (10 slides per profile) Remark 2 Empty cells indicate that data were not obtained due to the low signal intensities Remark 3 Definition of gene expression change Higher in N-fixing conditions: expression ratio (N-fixing conditions/non-N-fixing conditions) is greater than or equal to 2 AND score is less than 0.025 (at least 95% confident that the expresssion ratio of N-fixing conditions/non-N-fixing conditions is positive, i.e., higher in N-fixing conditions) Lower in N-fixing conditions: expression ratio (N-fixing conditions/non-N-fixing conditions) is less than or equal to 0.5 AND scores is greater than 0.975 (at least 95% confident that the expresssion ratio of N-fixing conditions/non-N-fixing conditions is negative, i.e., lower in N-fixing conditions) Remark 4 Mo strain (CGA753), V strain (CGA766), and Fe strain (CGA755) refer to Mo nitrogenase only strain, V nitrogenase only strain, and Fe nitrogenase only strain, respectively Remark 5 Plus V indicates that 10 µM V was added to the growth medium Col# 1 RPA# Col# 2 The average expression ratio (N-fixing conditions/non-N-fixing conditions) based on (maximum) 12 comparative experimental data points Red: average expression ratio is greater than or equal to 2 (greater than or equal to 2-fold higher in N-fixing conditionand Blue: average expression ratio is less than or equal to 0.5 (greater than or equal to 2-fold lower in N-fixing conditio Col# 3 Score [the probability of logarithmic ratio (N-fixing conditions/non-N-fixing conditions) of expression level below 0] determined by a Markov chain Monte Carlo simulation Red: score is less than 0.025 (the expression ratio is positive, i.e., high in N-fixing conditionand Blue: score is greater than 0.975 (the expression ratio is negative, i.e., low in N-fixing conditions Col# 4 Annotation Col# 1 Col# 2 Col# 3 Col# 2 Col# 3 Col# 2 Col# 3 Col# 2 Col# 3 Col# 2 Col# 3 Col# 4 Wild-type strain Wild-type strain Mo strain V strain Fe strain (plus V) (plus V) (CGA009) (CGA009) (CGA753) (CGA766) (CGA755) RPA# W AvRt W Sco WV AvRt WV Sco Mo AvRt Mo Sco V AvRt V Sco Fe AvRt Fe Sco Annotation RPA0001 0.665963 0.995 0.66581 0.9995 0.535337 0.9995 0.582471 0.997 0.648473 0.9685 dnaA chromosomal replication initiator protein DnaA 679:2097 forward MW:52624 RPA0002 0.832078 0.945 0.713654 0.999 0.750162 0.991 0.632156 0.999 0.700926 0.9985 dnaN DNA polymerase III beta subunit 2332:3450 forward MW:40401 RPA0003 recF putative RecF protein 3667:4833 forward MW:41676 RPA0004 0.589961 1 0.627573 1 0.876581 0.9285 0.546938 0.998 0.704026 0.991 gyrB DNA gyrase subunit B 5050:7491 forward MW:89311 RPA0005 0.948484 0.736 1.012589 0.448 0.905783 0.853 1.185123 0.0515 2.079792 0.002 hpd 4-hydroxyphenylpyruvate dioxygenase 7673:8791 reverse MW:40713 RPA0006 0.660193 0.987 0.620895 0.9975 0.767535 0.9625 0.990005 0.5265 0.873999 0.9175 CDS transcriptional regulator, AsnC family 8917:9396 forward MW:17592 RPA0007 1.004884 0.467 1.013173 0.462 1.086041 0.19 0.788753 0.9625 0.801843 0.965 CDS putative signal transduction histidine kinase with PAS/PAC domains 9442:10893 reverse MW:51220 RPA0008 0.972158 0.6615 1.094975 0.147 1.083926 0.193 1.013045 0.457 0.969496 0.6055 kaiB circadian clock protein 10890:11174 reverse MW:10217 RPA0009 1.157415 0.1305 1.104502 0.1365 0.883592 0.8835 0.886024 0.8 1.021125 0.4 kaiC circadian clock protein 11184:12875 reverse MW:61906 RPA0010 0.756573 0.93 0.542423 0.9885 0.642433 0.978 0.770893 0.7905 0.640031 0.98 CDS possible glutamate uptake transcriptional regulator, AsnC family 13269:13778 reverse MW:18704 RPA0011 1.538605 0.004 1.250146 0.0475 1.37407 0.011 1.331754 0.071 1.078848 0.3385 CDS conserved hypothetical protein 14266:14514 reverse MW:9325 RPA0012 1.435202 0.048 1.511813 0.0035 1.494955 0.012 1.798991 0.004 1.418852 0.0105 rdxS, fixS possible fixS 14516:14701 reverse MW:6468 RPA0013 1.215864 0.027 1.183082 0.0665 1.195945 0.101 1.239875 0.0345 0.788519 0.9025 rdxI, fixI putative cation (heavy metal) transporting ATPase 14692:16890 reverse MW:77870 RPA0014 1.229704 0.027 1.58493 0.005 1.21545 0.125 1.525197 0.0385 1.034979 0.385 rdxH, fixH conserved hypothetical protein 16925:17428 reverse MW:18109 RPA0015 1.476543 0.003 1.763539 0.001 1.377831 0.022 1.835532 0.0125 1.543146 0.027 fixG, rdxB 4Fe-4S ferredoxin, iron-sulfur binding domain 17445:18902 reverse MW:54555 RPA0016 1.995855 0.0005 1.991599 0 1.948835 0.001 2.142437 0.003 1.549919 0.0035 ccoP, fixP cytochrome-c oxidase fixP chain 19019:19900 reverse MW:31591 RPA0017 1.474059 0.014 1.710393 0.0015 1.54257 0.006 1.414015 0.04 1.094925 0.197 ccoQ, fixQ cytochrome oxidase subunit, small membrane protein 19908:20072 reverse MW:6267 RPA0018 2.109964 0 2.205291 0.0015 2.23222 0.0015 2.169297 0.0045 1.441704 0.0325 ccoO, fixO cytochrome-c oxidase fixO chain 20082:20816 reverse MW:27263 RPA0019 1.818109 0.002 1.738453 0.001 1.941932 0.006 1.832428 0.005 1.333838 0.005 ccoN, fixN cytochrome-c oxidase fixN chain, heme and copper binding subunit 20829:22475 reverse MW:61588 RPA0020 0.729271 0.9785 0.799716 0.968 0.92995 0.7345 0.764698 0.9105 0.708331 0.9925 panE1 Ketopantoate reductase ApbA/PanE 22786:23706 reverse MW:32340 RPA0021 0.823356 0.896 0.753434 0.9755 0.905621 0.7475 0.799699 0.886 0.802977 0.912 CDS possible short chain dehydrogenase 23779:24516 reverse MW:26621 RPA0022 CDS DSBA oxidoreductase 24637:25239 reverse MW:22293 RPA0023 1.016277 0.413 0.891777 0.8805 0.956305 0.701 0.832687 0.9565 0.926943 0.6955 gstA3 possible glutathione transferase 25362:26123 forward MW:28571 RPA0024 0.938735 0.7555 1.132245 0.062 0.912631 0.7995 1.017442 0.4495 1.023153 0.4225 CDS Short-chain dehydrogenase/reductase SDR 26235:27110 reverse MW:30727 RPA0025 1.071125 0.313 0.804989 0.9825 0.978916 0.614 0.794189 0.9775 0.837225 0.959 ggt1 gamma-glutamyltranspeptidase 27385:29118 reverse MW:60414 RPA0026 0.780263 0.993 0.72297 0.997 0.836173 0.9415 0.494706 0.9985 0.682774 0.9815 CDS Major Facilitator Superfamily (MFS) transporter 29224:30621 forward MW:49109 RPA0027 0.626608 0.974 0.539779 0.9995 0.565933 1 0.457924 0.9975 0.51349 0.999 aroG1 2-dehydro-3-deoxyphosphoheptonate aldolase 30837:31931 forward MW:38504 RPA0028 0.825066 0.9675 0.875109 0.914 0.58885 1 0.836575 0.9275 1.121169 0.266 purH bifunctional purine biosynthesis protein 31989:33581 reverse MW:55969 RPA0029 0.845467 0.9365 0.768642 0.996 0.811002 0.983 0.641503 0.999 0.83785 0.962 CDS conserved hypothetical protein 33767:35653 reverse MW:69043 RPA0030 0.574225 0.996 0.608447 0.9805 0.83391 0.9625 0.429529 0.999 0.575819 0.9985 CDS Bacterial Sun/eukaryotic nucleolar Nop1/Nop2 35820:37172 reverse MW:48051 RPA0031 0.720167 0.92 0.825327 0.7185 0.831532 0.8675 0.618629 0.9795 CDS conserved hypothetical protein 37325:37543 forward MW:7774 RPA0032 0.894084 0.841 1.033433 0.437 0.903145 0.8715 0.809264 0.8275 0.846422 0.946 CDS possible Staphylococcal nuclease homologues 37629:38204 forward MW:21361 RPA0033 1.241882 0.1865 0.77885 0.931 1.215192 0.037 0.945283 0.627 0.831397 0.878 CDS conserved hypothetical protein 38208:39092 reverse MW:32310 RPA0034 0.507185 1 0.39952 0.9995 0.542011 0.9995 0.338681 0.9995 0.306156 1 CDS possible flavin containing amine oxidase 39440:40897 forward MW:50840 RPA0035 0.606665 0.996 0.59874 0.9975 0.613304 1 0.657503 0.975 0.617981 0.908 pheT putative phenylalanine-tRNA ligase beta chain 40904:43315 reverse MW:85210 RPA0036 0.702134 0.981 0.813587 0.92 0.727408 0.9975 0.589327 0.9975 0.626656 0.942 CDS conserved unknown protein 43460:43939 reverse MW:17908 RPA0037 0.595524 0.9885 0.873054 0.9605 0.576278 0.9995 0.702 0.995 0.962009 0.6255 pheS phenylalanyl-tRNA synthetase, alpha-subunit 44200:45282 reverse MW:40115 RPA0038 1.078039 0.3495 1.017722 0.388 0.745839 0.987 0.846019 0.961 0.941254 0.694 rplT ribosomal protein L20 45426:45785 reverse MW:13300 RPA0039 0.917195 0.8105 1.179395 0.047 0.775479 0.985 1.0775 0.234 1.182074 0.0665 rpmI 50S ribosomal protein L35 45869:46069 reverse MW:7547 RPA0040 0.933369 0.6405 1.48114 0.016 1.220435 0.069 1.313212 0.0755 1.062968 0.299 infC translation initiation factor IF-3 46403:46981 reverse MW:21922 RPA0041 0.80406 0.96 0.681026 0.9775 0.678227 0.988 0.612673 0.9825 0.760538 0.991 CDS conserved unknown protein 47263:48048 forward MW:28350 RPA0042 1.023413 0.425 0.870792 0.841 0.919883 0.764 1.367083 0.06 1.290854 0.0575 CDS possible iron-sulfur cluster binding protein 48211:49323 reverse MW:40319 RPA0043 0.862491 0.925 1.049005 0.3565 0.81973 0.9355 0.978042 0.5835 0.979389 0.6025 CDS possible glutathione S-transferase 49368:50060 reverse MW:26063 RPA0044 0.768773 0.9845 1.020344 0.407 0.656237 0.9985 0.644429 0.9945 0.803942 0.905 bacA bacitracin resistance protein 50260:51066 forward MW:29341 RPA0045 0.707499 1 0.699705 0.9935 0.823524 0.9745 0.839708 0.9435 0.813824 0.9885 CDS putative NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 51116:52081 reverse MW:33871 RPA0046 0.601368 0.9915 0.724339 0.9965 0.682884 0.998 0.620636 0.9995 0.707856 0.9875 CDS 3'-5' exonuclease 52495:53109 forward MW:22696 RPA0047 0.673268 0.991 0.777338 0.995 0.743545 0.9745 0.598133 0.9945 0.72011 0.997 CDS conserved hypothetical protein 53339:54079 forward MW:26825 RPA0048 0.659016 0.985 0.777336
Load more

Recommended publications
  • Phylogenetic Screening for Possible Novel
    11 M060072591U NORTH-WEST UNIVERSITY tilt• YUNIBESITI YA BOKONE•BOPHIRIMA NOOROVVE S-UNIVERSITEIT PHYLOGENETIC SCREENING FOR POSSIBLE NOVEL ANTIBIOTIC PRODUCING ACTINOMYCETES FROM RHIZOSPHERIC SOIL SAMPLES COLLECTED FROM NGAKA MODIRI MOLEMA DISTRICT IN NORTH WEST PROVINCE, SOUTH AFRICA I BY MOBOLAJI FELICIA ADEGBOYE A thesis submitted in fulfilment of the requirements for the degree of DOCTOR OF PHILOSOPHY (BIOLOGY) DEPARTMENT OF BIOLOGICAL SCIENCES FACULTY OF SCIENCE, AGRICULTURE AND TECHNOLOGY NORTH-WEST UNIVERSITY, MAFIKENG CAMPUS SOUTH AFRICA Supervisor: Professor Olubukola 0. Babalola 2014 LIBRARY o MAFIKENG CAMPUS CALL NO.: 2021 -02- 0 4 DECLARATION I, the undersigned, declare that this thesis submitted to the North-West University for the degree of Doctor of Philosophy in Biology in the Faculty of Science, Agriculture and Technology, School of Environmental and Health Sciences, and the work contained herein is my original work with exemption to the citations and that this work has not been submitted at any other University in partial or entirely for the award of any degree. Name: Mobolaji Felicia Adegboye Signature: .....~ •·· ··· ····· ·· .. ··············· ..... Date: .... ~S.. .. ....a~ ·1·· ·'.}Q~i; ... ............ .... DEDICATION This work is dedicated to Almighty God for His faithfulness over my life and for making my helpers to be many. ii ACKNOWLEDGEMENTS I would like to express my deepest thanks, gratitude and appreciation to my supervisor and mentor, Prof. Olubukola 0. Babalola for giving me the opportunity to pursue my doctoral degree under her supervision and for her encouragement, help and kind support. Her invaluable advice, suggestions, discussions and guidance were a real support to me. I acknowledge with honour and gratitude the International Foundation for Science (IFS) for research grant (F/5330-1 ), Connect Africa Scholarship Award, H3ABioNet/SANBio Scholarship and North-West University for offering me bursary/scholarship award to pursue the PhD degree.
    [Show full text]
  • Exosomes Confer Chemoresistance to Pancreatic Cancer Cells By
    FULL PAPER British Journal of Cancer (2017) 116, 609–619 | doi: 10.1038/bjc.2017.18 Keywords: chemoresistance; exosomes; pancreatic cancer; ROS; microRNA Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK Girijesh Kumar Patel1, Mohammad Aslam Khan1, Arun Bhardwaj1, Sanjeev K Srivastava1, Haseeb Zubair1, Mary C Patton1, Seema Singh1,2, Moh’d Khushman3 and Ajay P Singh*,1,2 1Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA; 2Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL, USA and 3Department of Interdisciplinary Clinical Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA Background: Chemoresistance is a significant clinical problem in pancreatic cancer (PC) and underlying molecular mechanisms still remain to be completely understood. Here we report a novel exosome-mediated mechanism of drug-induced acquired chemoresistance in PC cells. Methods: Differential ultracentrifugation was performed to isolate extracellular vesicles (EVs) based on their size from vehicle- or gemcitabine-treated PC cells. Extracellular vesicles size and subtypes were determined by dynamic light scattering and marker profiling, respectively. Gene expression was examined by qRT-PCR and/or immunoblot analyses, and direct targeting of DCK by miR-155 was confirmed by dual-luciferase 30-UTR reporter assay. Flow cytometry was performed to examine the apoptosis indices and reactive oxygen species (ROS) levels in PC cells using specific dyes. Cell viability was determined using the WST-1 assay. Results: Conditioned media (CM) from gemcitabine-treated PC cells (Gem-CM) provided significant chemoprotection to subsequent gemcitabine toxicity and most of the chemoresistance conferred by Gem-CM resulted from its EVs fraction.
    [Show full text]
  • Integrative Systems Biology– Renal Diseases: a Road to a Holist View of Chronic Disease Mechanism
    Integrative Systems biology– Renal Diseases: A road to a holist view of chronic disease mechanism Matthias Kretzler Div. Nephrology / Internal Medicine Computational Medicine and Bioinformatics University of Michigan Medical School The challenge in chronic disease • Descriptive disease categorization with multiple pathogenetic mechanisms § Problems of ‘mixed bag’ diseases: • Unpredictable disease course and response to therapy • Nephrology as an ‘art of trial and error’ • Shift in our disease paradigms: § Mechanism based patient management • Define the disease process active in the individual patient – Base prognosis on specific disease process – Target therapy to interfere with the mechanism currently destroying endorgan function Molecular Nephrology approach Clinical outcome research Genetics Molecular Pathology Molecular Epigenetics Phenotyping Genomics Functional Clinical research Disease Genomics Biobanks Proteomics Model systems Animal models Molecular interaction In vitro tissue culture model systems Organ culture and development Tower of Babylon: Search for the universal language for the medicine of the 21st century Pieter Bruegl: 1563. Kunsthistorisches Museum Wien Molecular Nephrology approach Clinical outcome research Genetics Molecular Pathology Molecular Epigenetics Phenotyping Genomics Functional Clinical research Disease Genomics Integrative Biobanks Proteomics Biology (Physiology) Model systems Animal models Molecular interaction of renal disease In vitro tissue culture model systems Organ culture and development Systems
    [Show full text]
  • Knockdown of RRM1 with Adenoviral Shrna Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
    International Journal of Molecular Sciences Article Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells Xia Zhang 1, Rikiya Taoka 1,*, Dage Liu 2, Yuki Matsuoka 1, Yoichiro Tohi 1 , Yoshiyuki Kakehi 1 and Mikio Sugimoto 1 1 Department of Urology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan; [email protected] (X.Z.); [email protected] (Y.M.); [email protected] (Y.T.); [email protected] (Y.K.); [email protected] (M.S.) 2 Department of General Thoracic Surgery, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-87-891-2202 Abstract: RRM1—an important DNA replication/repair enzyme—is the primary molecular gem- citabine (GEM) target. High RRM1-expression associates with gemcitabine-resistance in various cancers and RRM1 inhibition may provide novel cancer treatment approaches. Our study eluci- dates how RRM1 inhibition affects cancer cell proliferation and influences gemcitabine-resistant bladder cancer cells. Of nine bladder cancer cell lines investigated, two RRM1 highly expressed cells, 253J and RT112, were selected for further experimentation. An RRM1-targeting shRNA was Citation: Zhang, X.; Taoka, R.; Liu, cloned into adenoviral vector, Ad-shRRM1. Gene and protein expression were investigated using D.; Matsuoka, Y.; Tohi, Y.; Kakehi, Y.; real-time PCR and western blotting.
    [Show full text]
  • Tremblay Robinlee.Pdf
    Expression and Characterisation ofa Gene Enc oding RbpD, an RNA- Bind ing Protein in Anabaena sp. strain PeC 7120 by Rob in lee Tremblay A lhesis submitted to the Scltool of Graduale Studies in partial fulfilment of the requirements fOl" the degree of Master of Science Department of BiochemistrylFacultyof Science Memorial University of Newfoundland January 2000 SI.JOM'S Newfoun dland Abs t ra ct The RNA-binding protein RbpD, from the cyano bacterium Anaba ena sp, strain Pe C 7120 was expressed in £Sch~ ric h ia coli and successfully purified using me IMPACT I system (New England Biolabs). The rbp D gene was cloned into the pCYBt expre ssion vector by using polymerase chain reaction to introduce Ndel and SapI restriction sites at the 5' end 3' ends of the gene respect ively. The 3'.-end mutagenesis also chan ged the stop codon into a cysteine codon. The resulting gene encoded a fusion protein consisting of RbpD, the Saccharomyces cerev isiae VMA intein and a chitin binding domain.. Expressi on of the fusion protein was observed in £ coli strain MCI061 but Western blot analysis using an intein-directed ant ibody indicated that significant in vivo fmeln-direcred splicing of the fusion protein occurred. We were unable to eliminate this problem; no fusion protein expression was observed in 8 other E coli strains tested. Wild -type RbpD was purified following binding of the fusion protein 10 a chitin column and overnight cleavage in the presence of a reducing agent, dlthicthrehc l. A number of modifications to the manufacturer' s purification protocol were found to be necessary for success ful purification.
    [Show full text]
  • Taurine Reduction in Anaerobic Respiration of Bilophila Wadsworthia RZATAU
    APPLIED AND ENVIRONMENTAL MICROBIOLOGY, May 1997, p. 2016–2021 Vol. 63, No. 5 0099-2240/97/$04.0010 Copyright © 1997, American Society for Microbiology Taurine Reduction in Anaerobic Respiration of Bilophila wadsworthia RZATAU HEIKE LAUE, KARIN DENGER, AND ALASDAIR M. COOK* Faculta¨t fu¨r Biologie, Universita¨t Konstanz, D-78434 Konstanz, Germany Received 7 November 1996/Accepted 18 February 1997 Organosulfonates are important natural and man-made compounds, but until recently (T. J. Lie, T. Pitta, E. R. Leadbetter, W. Godchaux III, and J. R. Leadbetter. Arch. Microbiol. 166:204–210, 1996), they were not believed to be dissimilated under anoxic conditions. We also chose to test whether alkane- and arenesulfonates could serve as electron sinks in respiratory metabolism. We generated 60 anoxic enrichment cultures in mineral salts medium which included several potential electron donors and a single organic sulfonate as an electron sink, and we used material from anaerobic digestors in communal sewage works as inocula. None of the four aromatic sulfonates, the three unsubstituted alkanesulfonates, or the N-sulfonate tested gave positive enrichment cultures requiring both the electron donor and electron sink for growth. Nine cultures utilizing the natural products taurine, cysteate, or isethionate were considered positive for growth, and all formed sulfide. Two clearly different pure cultures were examined. Putative Desulfovibrio sp. strain RZACYSA, with lactate as the electron donor, utilized sulfate, aminomethanesulfonate, taurine, isethionate, and cysteate, converting the latter to ammonia, acetate, and sulfide. Strain RZATAU was identified by 16S rDNA analysis as Bilophila wadsworthia. In the presence of, e.g., formate as the electron donor, it utilized, e.g., cysteate and isethionate and converted taurine quantitatively to cell material and products identified as ammonia, acetate, and sulfide.
    [Show full text]
  • Purification and Characterisation of a Protease (Tamarillin) from Tamarillo Fruit
    Purification and characterisation of a protease (tamarillin) from tamarillo fruit Item Type Article Authors Li, Zhao; Scott, Ken; Hemar, Yacine; Zhang, Huoming; Otter, Don Citation Li Z, Scott K, Hemar Y, Zhang H, Otter D (2018) Purification and characterisation of a protease (tamarillin) from tamarillo fruit. Food Chemistry. Available: http://dx.doi.org/10.1016/ j.foodchem.2018.02.091. Eprint version Post-print DOI 10.1016/j.foodchem.2018.02.091 Publisher Elsevier BV Journal Food Chemistry Rights NOTICE: this is the author’s version of a work that was accepted for publication in Food Chemistry. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Food Chemistry, [, , (2018-02-16)] DOI: 10.1016/j.foodchem.2018.02.091 . © 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ Download date 29/09/2021 23:19:14 Link to Item http://hdl.handle.net/10754/627180 Accepted Manuscript Purification and characterisation of a protease (tamarillin) from tamarillo fruit Zhao Li, Ken Scott, Yacine Hemar, Huoming Zhang, Don Otter PII: S0308-8146(18)30327-3 DOI: https://doi.org/10.1016/j.foodchem.2018.02.091 Reference: FOCH 22475 To appear in: Food Chemistry Received Date: 25 October 2017 Revised Date: 13 February 2018 Accepted Date: 16 February 2018 Please cite this article as: Li, Z., Scott, K., Hemar, Y., Zhang, H., Otter, D., Purification and characterisation of a protease (tamarillin) from tamarillo fruit, Food Chemistry (2018), doi: https://doi.org/10.1016/j.foodchem.
    [Show full text]
  • TRACE: Tennessee Research and Creative Exchange
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 8-2009 Structure-Function Studies of the Large Subunit of Ribonucleotide Reductase from Homo sapiens and Saccharomyces cerevisiae James Wesley Fairman University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Biochemistry, Biophysics, and Structural Biology Commons Recommended Citation Fairman, James Wesley, "Structure-Function Studies of the Large Subunit of Ribonucleotide Reductase from Homo sapiens and Saccharomyces cerevisiae. " PhD diss., University of Tennessee, 2009. https://trace.tennessee.edu/utk_graddiss/49 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by James Wesley Fairman entitled "Structure- Function Studies of the Large Subunit of Ribonucleotide Reductase from Homo sapiens and Saccharomyces cerevisiae." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Doctor of Philosophy, with a major in Biochemistry and Cellular and Molecular Biology. Chris G. Dealwis,
    [Show full text]
  • Mitigation of ALS Pathology by Neuron-Specific Inhibition of Nuclear Factor Kappa B Signaling
    The Journal of Neuroscience, June 24, 2020 • 40(26):5137–5154 • 5137 Neurobiology of Disease Mitigation of ALS Pathology by Neuron-Specific Inhibition of Nuclear Factor Kappa B Signaling Kallol Dutta,1 Sai Sampath Thammisetty,1 Hejer Boutej,1 Christine Bareil,1 and Jean-Pierre Julien1,2 1CERVO Brain Research Centre, Québec City, Québec G1J 2G3, Canada, and 2Department of Psychiatry and Neuroscience, Université Laval, Québec City, Québec G1V 0A6, Canada To investigate the role of neuronal NF-jB activity in pathogenesis of amyotrophic lateral sclerosis (ALS), we generated trans- genic mice with neuron-specific expression of a super-repressor form of the NF-jB inhibitor (IjBa-SR), which were then crossed with mice of both sexes, expressing ALS-linked gene mutants for TAR DNA-binding protein (TDP-43) and superoxide dismutase 1 (SOD1). Remarkably, neuronal expression of IjBa-SR transgene in mice expressing TDP-43A315T or TDP-43G348C mice led to a decrease in cytoplasmic to nuclear ratio of human TDP-43. The mitigation of TDP-43 neuropathology by IjBa-SR, which is likely due to an induction of autophagy, was associated with amelioration of cognitive and motor deficits as well as reduc- tion of motor neuron loss and gliosis. Neuronal suppression of NF-jB activity in SOD1G93A mice also resulted in neuroprotection with reduction of misfolded SOD1 levels and significant extension of life span. The results suggest that neuronal NF-jB signaling constitutes a novel therapeutic target for ALS disease and related disorders with TDP-43 proteinopathy. Key words: amyotrophic lateral sclerosis; frontotemporal dementia; IjB suppressor; NF-jB; superoxide dismutase; TDP-43 Significance Statement This study reports that neuron-specific expression of IkB super-repressor mitigated behavioral and pathologic changes in transgenic mouse models of amyotrophic lateral sclerosis expressing mutant forms of either Tar DNA-binding protein 43 or superoxide dismutase.
    [Show full text]
  • ERK5 Binding Partners
    Supplementary Table 1: ERK5 binding partners id Protein IDs Protein namesGene namesRazor + uniqueSequence peptides coverageLFQ intensity [%]LFQ FL_m_01 intensityLFQ FL_m_02 intensityLFQ FL_m_03 intensityLFQ FL_p_01 intensityLFQ FL_p_02 intensityLFQ FL_p_03 intensityLFQ MU_p_01 intensityLFQ MU_p_02 intensitynormalized MU_p_03 normalizedLog2 IFL_m_01 normalizedLog2 IFL_m_02 normalizedLog2 IFL_m_03 normalizedLog2 IFL_p_01 normalizedLog2 IFL_p_02 normalizedLog2 IFL_p_03 normalizedLog2 IMU_p_01 normalizedLog2 IMU_p_02 medianLog2 IMU_p_03 - mediam FL median Mutst dev - st dev fl st dev mut cluster1 cluster2 cluster3 950 H7BXZ6 MitochondrialRHOT1 Rho GTPase 2 6.5 1.08E+08 26.77 26.77 + 405 B7WPL0 Synembryn-BRIC8B 2 6.1 9.55E+07 26.75 26.75 + 780 F6RFD5 Destrin DSTN 5 37.8 3.94E+07 25.49 25.49 + 360 B1AN48 Small proline-richSPRR3 protein 3 2 10.1 3.65E+07 25.24 25.24 + 1376 P02808 Statherin STATH 2 54.8 3.05E+07 25.12 25.12 + 196 A0A0A0MTI6Elongation ofELOVL5 very long chain fatty2 acids protein8.4 1.92E+07 1.52E+07 24.35 24.09 24.22 0.188066 + 2157 Q13163-4 Dual specificityMAP2K5 mitogen-activated6 protein18.7 kinase kinase 5 9.04E+06 2.09E+07 1.04E+07 8.78E+06 1.28E+07 1.06E+07 23.11 24.49 23.53 23.01 23.4 22.9 23.53 23.01 0.704014 0.263334 + 2702 Q96AB3-3 IsochorismataseISOC2 domain-containing2 protein28.1 2, mitochondrial 8.02E+06 23.1 23.1 + 64 A0A087WW54DEP domain-containingDEPDC7 protein 75 9.6 4.88E+06 7.56E+06 1.20E+07 3.13E+06 22.21 23.03 23.69 21.54 23.03 21.54 0.742829 + 1673 P30837 Aldehyde dehydrogenaseALDH1B1 X, mitochondrial5 13.7
    [Show full text]
  • ANABOLISM III: Biosynthesis Amino Acids & Nucleotides
    BI/CH 422/622 ANABOLISM OUTLINE: Photosynthesis Carbohydrate Biosynthesis in Animals Biosynthesis of Fatty Acids and Lipids Biosynthesis of Amino Acids and Nucleotides Nitrogen fixation nitrogenase Nitrogen assimilation Glutamine synthetase Glutamate synthase Amino-acid Biosynthesis non-essential essential Nucleotide Biosynthesis RNA precursors purines pyrimidines DNA precursors deoxy-nucleotides Biosynthesis of secondary products of amino acids ANABOLISM III: Biosynthesis Amino Acids & Nucleotides Dr. Kornberg: Lecture 04.26.17 (0:00-5:06) 5 min 1 Biosynthesis Amino Acids & Nucleotides How are Ribonucleic Acid Precursors So far: converted to Deoxyribonucleic Acid GMPàGDPàGTP Precursors? ….....and how is dTTP made? AMPàADPàATP 2’C-OH bond is directly reduced to 2’-H UMPàUDPàUTPà bond …without activating the carbon for CDPßCTP dehydration, etc.! catalyzed by ribonucleotide reductase Specific kinases, Non-specific kinase, e.g., UMP kinase, nucleoside GMP kinase, diphosphate kinase Very unique enzyme in all of biochemistry – use of free Adenylate kinase (works on both oxy- and radicals etc. deoxy-ribose GDPàdGDP nucleosides) Mechanism: Two H atoms are donated ADPàdADP by NADPH and carried by thioredoxin or glutaredoxin to the active site. UDPàdUDP –Substrates are the NDPs and the products CDPàdCDP are dNDP. Biosynthesis Amino Acids & Nucleotides Source of Reducing Structure of Ribonucleotide Reductase a2 are regulatory Electrons for and half the Ribonucleotide catalytic site; need to be reduced. Reductase b 2 are the other half (a b ) of the active site, 2 2 and the free- radical generators • NADPH serves as the electron donor. • Funneled through glutathione or JoAnne Stubbe thioredoxin pathways (1946– ) 2 •Most forms of enzyme have two catalytic/ regulatory subunits and two radical- generating subunits.
    [Show full text]
  • WO 2017/083351 Al 18 May 2017 (18.05.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/083351 Al 18 May 2017 (18.05.2017) P O P C T (51) International Patent Classification: MCAVOY, Bonnie D.; 110 Canal Street, Lowell, Mas- C12N 1/20 (2006.01) A01N 41/08 (2006.01) sachusetts 01854 (US). C12N 1/21 (2006.01) C07C 403/24 (2006.01) (74) Agent: JACOBSON, Jill A.; FisherBroyles, LLP, 2784 C12N 15/75 (2006.01) A23L 33/175 (2016.01) Homestead Rd. #321, Santa Clara, California 9505 1 (US). A23K 10/10 (2016.01) A23L 5/44 (2016.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US20 16/06 1081 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, ' November 2016 (09.1 1.2016) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (30) Priority Data: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 62/252,971 ' November 2015 (09.
    [Show full text]